Skip to main content
Clinical Trials/JPRN-UMIN000009822
JPRN-UMIN000009822
Recruiting
Phase 2

Randomized phase II trial of neoadjuvant Chemotherapy with Gemcitabine and S-1 vs. without neoadjuvant chemotherapy in patients with resectable pancreatic cancer - Randomized phase II trial of GS neoadjuvant therapy for patients with resectable pancreatic cancer (CAP-004)

Chiba study group of adjuvant chemotherapy for pancreatic cancer0 sites74 target enrollmentJanuary 20, 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Resectable pancreatic cancer
Sponsor
Chiba study group of adjuvant chemotherapy for pancreatic cancer
Enrollment
74
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 20, 2013
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Chiba study group of adjuvant chemotherapy for pancreatic cancer

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Inadequate physical condition for gemcitabine or S\-1 treatmetn according to manufacture's instruction 2\. Sever myelosuppression 3\. Pregnancy, breast feeding, or women who desire to preserve fecundity 4\. Sever renal dysfunction 5\. Sever hepatic dysfunction 6\. With other anticancer treatment 7\. With flucitocine or warfarin potassium treatment 8\. With pulmonary fibrosis 9\. With history of radiation to lung field 10\. Active infectious disease 11\. Massive pleural effusion 12\. With distant metastasis 13\. Active malignancies other than pancreatic cancer 14\. Severe angina, cardiac infurction within 3 months at the registration, and severe hear failure 15\. Severe diabetes or hypertension 16\. Severe mental disorder 17\. Inadequate physical condition, as diagnosed by primary physician

Outcomes

Primary Outcomes

Not specified

Similar Trials